| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-523 | |
| Phytochemical name or plant extracts | Fenugreek extract | |
| PMID | 33889009 | |
| Literature evidence | It requires a detailed analysis to understand the effect of FSE to induce the apoptosis through the multiple signaling pathways at varying concentrations. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic and Chloroformic extract | |
| Source of phytochemicals or plant Extracts | Trigonella foenum-graecum | |
| Geographical availability | Afghanistan, Iran, Iraq, Pakistan | |
| Plant parts | Seeds | |
| Other cancers | Breast cancer, Prostate cancer, Pancreatic cancer, Colorectal cancer, Leukemia | |
| Target gene or protein | PI3K, Bax, Bcl-2 | |
| Gene or Protein evidence | Fenugreek seed extract stimulates the insulin-mediated molecular pathway in adipocytes and hepatic cells following the phosphorylation of many genes, including insulin receptor, p85 subunit of PI3K in vitro. FSE induced a significant increase in the mitochondrial depolarization, ROS as well as a Bax/Bcl-2 ratio, and also exhibited the mitochondrial associated p53 signaling pathway. | |
| Target pathways | p53 signaling pathway | |
| IC50 | 150 μg/mL against MCF-7 40 μg/mL against SKBR-3 38.51 μg/mL against MDA-MB-231 | |
| Potency | FSE may be a potential anti-cancer agent in combination with chemotherapeutic agents. | |
| Cell line/ mice model | MCF-7, MDA-MB-231, KAIMRC1, SK-BR3, HL60, K562, HCT8, HCT116 | |
| Additional information | The flow cytometry analysis revealed that FSE induced a significant shift from G2/M, and polyploidy (>G) at higher concentrations that suggested the activation of p53-mediated mitotic catastrophe, consequently leading to apoptosis. | |
| PubChem ID | NA | |
| Additional PMIDs | 33116517 22471470 34675483 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:523957-1 | |
| Safety | The nontoxic effect of FSE in mice suggests to utilize it safely for pharmaceutical formulations in different cancer systems. |